Immatics N.V.
- Last sale
- Nov 12, 2026 · -2.99%
- Market cap
- $871.46M
- 134.07M shares
- Filings
- 248
—
—
—FY 2025N/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025N/M FY25 yoy
FY 2025+46.1% FY25 yoy
- $871.46M
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €183,832,000 | reported | |
| FY 2024 | 2024-12-31 | €148,079,000 | reported | |
| FY 2023 | 2023-12-31 | €118,663,000 | reported | |
| FY 2022 | 2022-12-31 | €106,779,000 | reported | |
| FY 2021 | 2021-12-31 | €87,574,000 | reported | |
| FY 2020 | 2020-12-31 | €67,085,000 | reported | |
| FY 2019 | 2019-12-31 | €40,091,000 | reported | |
| FY 2018 | 2018-12-31 | €33,971,000 | reported |
Biological products, except diagnostic substances
Immatics N.V. is the 47th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
ODTXOdyssey Therapeutics, Inc.———$969.5M
IMTXImmatics N.V. (this company)———$871.5M
MGTXMeiraGTx Holdings plc$81.4M144.6%140.3%$858.1MGLUEMonte Rosa Therapeutics, Inc.$123.7M63.5%31.2%$793.0MSLDBSolid Biosciences Inc.———$781.8MAURAAura Biosciences, Inc.———$740.5MATTOAttovia Therapeutics, Inc.———$723.6MPRMEPrime Medicine, Inc.$4.6M55.3%4,342.4%$705.9MFDMT4D Molecular Therapeutics, Inc.$85.2M230,194.6%164.4%$682.1MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Immatics N.V. · CIK 1809196 · Engraved from SEC EDGAR